Methods and compositions for treating diseases and conditions

Inventors

Ford, Anthony P. • PATON, Julian

Assignees

Afferent Pharmaceuticals Inc

Abstract

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.

Core Innovation

The disclosure relates to therapeutic methods for treating sleep apnea in a subject in need thereof. The methods include administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and further include a specified compound or a pharmaceutically acceptable salt of a specified substance.

Formula (I) is defined by substituent parameters R1 and R2, with exemplary formula (I) compounds listed in Table 1. The document characterizes sleep apnea by central sleep apnea, obstructive sleep apnea, or mixed sleep apnea, and by apneic event frequency thresholds including more than about 5 apneic events per hour and more than about 15 apneic events per hour.

The disclosure also uses language directed to carotid body tonicity/activity, carotid glomus, and modulation of carotid chemosensory afferent discharge. In some embodiments, it includes a P2X3 receptor antagonist and/or a P2X2/3 receptor antagonist, and relates to ATP-gated purinergic signaling linked to carotid body hypertonicity and hypersensitivity.

Claims Coverage

The claim coverage includes three independent claims focused on methods of treating sleep apnea by administering an effective amount of a compound of formula (I), a specified compound, or a pharmaceutically acceptable salt. Across the independent claims, the inventive features center on the sleep apnea treatment framework and specific compound or salt selection, with dependent refinements to sleep apnea subtype and apneic-event frequency thresholds.

Across the independent claims, the core coverage is a sleep apnea treatment method in which an effective amount is administered, with the identity of the administered agent defined as either a compound of formula (I), a specific compound, or a pharmaceutically acceptable salt. Dependent claim refinements narrow the treatment to central or obstructive sleep apnea and apply apneic-event frequency thresholds.

Stated Advantages

Documented Applications